0001415889-24-021370.txt : 20240815
0001415889-24-021370.hdr.sgml : 20240815
20240815165935
ACCESSION NUMBER: 0001415889-24-021370
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240813
FILED AS OF DATE: 20240815
DATE AS OF CHANGE: 20240815
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Torley Helen
CENTRAL INDEX KEY: 0001528185
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32335
FILM NUMBER: 241213231
MAIL ADDRESS:
STREET 1: C/O ONYX PHARMACEUTICALS, INC.
STREET 2: 249 EAST GRAND AVE.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: HALOZYME THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001159036
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 880488686
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12390 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 794-8889
MAIL ADDRESS:
STREET 1: 12390 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: HALOZYME THERAPEUTICS INC
DATE OF NAME CHANGE: 20040312
FORMER COMPANY:
FORMER CONFORMED NAME: GLOBAL YACHT SERVICES INC
DATE OF NAME CHANGE: 20010912
4
1
form4-08152024_080831.xml
X0508
4
2024-08-13
0001159036
HALOZYME THERAPEUTICS, INC.
HALO
0001528185
Torley Helen
C/O HALOZYME THERAPEUTICS, INC.
12390 EL CAMINO REAL
SAN DIEGO
CA
92130
true
true
false
false
PRESIDENT AND CEO
1
Common Stock
2024-08-13
4
M
0
10000
13.87
A
686744
D
Common Stock
2024-08-13
4
S
0
10000
56.249
D
676744
D
Common Stock
2024-08-14
4
M
0
10000
13.87
A
686744
D
Common Stock
2024-08-14
4
S
0
3263
56.219
D
683481
D
Common Stock
2024-08-14
4
S
0
6537
57.732
D
676944
D
Common Stock
2024-08-14
4
S
0
200
58.17
D
676744
D
Common Stock
2024-08-15
4
M
0
10000
13.87
A
686744
D
Common Stock
2024-08-15
4
S
0
10000
57.949
D
676744
D
Option to Purchase Common Stock
13.87
2024-08-13
4
M
0
10000
13.87
D
2025-02-06
Common Stock
10000
100000
D
Option to Purchase Common Stock
13.87
2024-08-14
4
M
0
10000
13.87
D
2025-02-06
Common Stock
10000
90000
D
Option to Purchase Common Stock
13.87
2024-08-15
4
M
0
10000
13.87
D
2025-02-06
Common Stock
10000
80000
D
The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 22, 2024 in accordance with Rule 10b5-1.
Represents a weighted average sales price per share. The shares were sold at prices ranging from $55.81 to $56.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Represents a weighted average sales price per share. The shares were sold at prices ranging from $55.96 to $56.94. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Represents a weighted average sales price per share. The shares were sold at prices ranging from $57.10 to $58.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Represents a weighted average sales price per share. The shares were sold at prices ranging from $57.405 to $58.175. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 6, 2015.
/s/ James R. Oehler, Attorney-in-Fact
2024-08-15